Andrew White
Associate Professor
Centre Director
MBBS/PhD
andrew.white@sydney.edu.au

Biography
Director, Centre for Vision Research
Group Leader, Glaucoma Cell Biology Lab
A/Prof White is a highly respected expert in the field of glaucoma, with over 20 years of experience in both clinical practice and research. His combined MBBS/PhD degree from the University of Sydney and numerous publications in prestigious journals highlight his extensive knowledge and commitment to advancing the field. A/Prof White is passionate about translating his research findings into tangible benefits for patients, and he actively collaborates with clinicians and industry partners to develop effective treatments and diagnostic tools. Under the direction of A/Prof Andrew White, the WIMR is at the forefront of groundbreaking research in glaucoma. With a dedicated research group and state-of-the-art facilities, is committed to developing innovative solutions for improving the lives of millions affected by glaucoma worldwide.
Research interests
Developing new neuroprotective therapies: We are investigating novel approaches to protect the optic nerve, the crucial pathway for vision, from damage caused by glaucoma.
Understanding wound healing modulation in glaucoma: We are exploring how to improve tissue healing after surgery to optimize outcomes for glaucoma patients.
Using genetic profiling and hyperspectral imaging of the retina to identify people at high risk of developing progressive glaucoma suitable for early intervention treatments
Utilizing new biomaterials in glaucoma surgery and wound repair: We are researching the use of innovative materials to enhance surgical outcomes and minimize complications.
Harnessing the power of artificial intelligence (AI): We are developing AI-based technologies to predict patients at risk of glaucoma progression and facilitate early diagnosis.
Making glaucoma and diabetic retinopathy diagnosis easier utilizing with smartphone-based photography with AI based clinical support.
Building a robust community-based model of care: We are establishing a new model for delivering effective and accessible eye care to patients with glaucoma and other chronic eye conditions.
Adjunct roles
Head of Department and consultant Ophthalmologist, Westmead Hospital | |
Clinical A/Prof, Westmead Hospital & University of Sydney | |
Director, Community Eye Care Centre, Western Sydney | |
Director, Westmead C-Eye-C Project: Community Based Eye Care for Chronic Conditions | |
Co-Chair, Agency for Clinical Innovation Ophthalmology Network Governing Body | |
Chair, Westmead Eye Clinic Redesign Project: Cataract Pathways | |
Associate Advisory Board Member, World Glaucoma Association | |
NSW Representative Council Member, RANZCO |
Recent publications

Inhibitory Effects on Human Tenon Fibroblast Migration and Reactive Oxygen Species Production in Cell Culture. TVST.
November 2018

Dendritic cells in the cornea during Herpes simplex viral infection and inflammation. Survey of Ophthalmology
November 2018

The Role of Reactive Oxygen Species in the Pathogenesis and Treatment of Retinal Diseases. Experimental Eye Research
November 2020

Tissue resident memory T cells inhabit the deep human conjunctiva. Scientific Reports
November 2022

Modulation of Fibroblasts in Conjunctival Wound Healing. Opthamology
November 2018
Additional information
https://www.personaleyes.com.au/our-doctors-and-ophthalmologists/dr-andrew-white
Google Scholar: Andrew White – Google Scholar
LinkedIn: https://www.linkedin.com/in/andrew-white-60718721/?originalSubdomain=au
https://glaucoma.org.au/node/457
USYD link – https://www.sydney.edu.au/medicine-health/about/our-people/academic-staff/andrew-white.html
Current grants
MRFF -2023; MRF2025723: Implementing a novel model of management for glaucoma using polygenic risk profiling. Funding Amount: $$2,934,013.14 | ||
NHMRC -2023. 2024299: SINERRGI SLT laser RCT Funding Amount: $400,000.00 | ||
Zeiss Australia – 2022 • Premium Multifocal Lens Experience in a Public Hospital Setting • Funding Amount: $50,000 | ||
Glaucoma Australia – 2021 • Project: A Novel Technology for the Early Detection and Monitoring of Glaucoma • Funding Amount: $68,262 | ||
Norma Hill Foundation – 2020 to Present • Project: Developing a Model for Degenerative Retinal Conditions • Funding Amount: $65,000 per year for five years | ||
Allergan Unrestricted Research Grant – 2020 • Project: A New Intervention to Prevent Ocular Inflammation and Fibrosis • Funding Amount: $59,889.78 |